New Indication Approved for a Pfizer Biosimilar
On behalf of Pfizer, it is our pleasure to inform you that on February 9th, 2021, Pfizer received FDA approval for the inclusion of epithelial ovarian, fallopian tube, and primary peritoneal cancer to the indications of ZIRABEV® (bevacizumab-bvzr).
There were also updates to align the ZIRABEV USPI with that of the reference product, AVASTIN incorporating revisions related to wound healing and the addition of adverse drug reactions, arterial aneurysms, dissections, and rupture to the Post Marketing Experience section.
ZIRABEV is currently the only bevacizumab biosimilar to be granted approval for epithelial ovarian, fallopian tube, and primary peritoneal cancer indications.
Please review the ZIRABEV Full Prescribing Information, including BOXED WARNINGS, for detailed information.
Product information is listed in the table below.
|ZIRABEV Product Information|
|Unit of Sale||100 mg/4 mL SDV||400 mg/16 mL SDV|
Unit of Sale Quantity
|1 vial per carton||1 vial per carton|
|Q-Code||Q5118: Injection, bevacizumab-bvzr, biosimilar (ZIRABEV), 10 mg|
Note: WAC price is a manufacturer’s undiscounted price and is not inclusive of contracts, rebates, or other discounts.